Q-omics provides the consensus-scored RPL26L1 profile across patient tissues and cancer cell-line models. RPL26L1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL26L1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, RPL26L1 protein abundance shows 21,834 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where RPL26L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26L1 survival associations across molecular data types. RPL26L1 RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26L1 RNA expression–survival associations across cancer types. High RPL26L1 expression shows unfavorable associations in HNSC, UVM, KICH, LIHC, SCLC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL26L1 RNA expression.
This table summarizes RPL26L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL26L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26L1 shows higher tumor expression in KIRC, COAD, HNSC, BLCA, LIHC and LUAD. The KIRC box plot shows higher RPL26L1 RNA expression in tumor versus normal tissue (log2 FC = +0.556, t-test p < 0.001).
This table shows molecular features associated with RPL26L1 in patient tissues and cancer cell lines. In patient samples, RPL26L1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL26L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
